Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer
Purpose In recent years, anti-Mullerian hormone (AMH) has been considered a reliable index of ovarian reserve. There are few data on AMH values in thyroid cancer. The aim of this study was to evaluate AMH levels in pre-menopausal women with a history of low-risk thyroid cancer. Methods Thirty-four w...
Gespeichert in:
| Veröffentlicht in: | Endocrine 2018-06, Vol.60 (3), p.516-523 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 523 |
|---|---|
| container_issue | 3 |
| container_start_page | 516 |
| container_title | Endocrine |
| container_volume | 60 |
| creator | Giusti, Massimo Mittica, Miranda Comite, Paola Campana, Claudia Gay, Stefano Mussap, Michele |
| description | Purpose
In recent years, anti-Mullerian hormone (AMH) has been considered a reliable index of ovarian reserve. There are few data on AMH values in thyroid cancer. The aim of this study was to evaluate AMH levels in pre-menopausal women with a history of low-risk thyroid cancer.
Methods
Thirty-four women (aged 40.7 ± 6.7 years) were studied 7.1 ± 0.9 years after surgery and at least one RAI treatment. A group of 23 thyroid cancer women (41.6 ± 7.4 years) who had undergone only thyroidectomy served as controls. AMH, follicle-stimulating hormone (FSH) and estradiol were assayed on days 2–3, and prolactin and progesterone levels on days 21–24 of the menstrual cycle.
Results
Pregnancy (RAI group 62%; control group 61%) and miscarriage rates (18% and 26%) were similar. AMH levels were similar in the RAI (10.7 ± 1.7 pmol/l) and control (17.5 ± 4.7 pmol/l) groups. Regular menses were reported in 41% and 52% of RAI and control subjects, respectively. Non-ovulatory cycles were noted in 26% and 35% of RAI and control women, respectively. AMH levels were found to be negatively correlated with age (RAI group
P
= 0.0003; control group
P
= 0.0001) and FSH, and positively correlated with progesterone, but not with the other hormonal parameters.
Conclusions
AMH should replace FSH in the evaluation of gonadal reserve in pre-menopausal thyroid cancer women. At present, age is the only predictor of AMH levels. About one out of two women with a history of thyroid cancer suffers from menstrual dysregulation, but infertility must be considered a low risk. |
| doi_str_mv | 10.1007/s12020-017-1510-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989535487</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1989535487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-2c69e8b1e0bd4870c04888f1c5bb5af47148fec6987f057f74460c734b98783d3</originalsourceid><addsrcrecordid>eNp1kc2OFSEQhYnROD_6AG4MiRs3aAHNhV5OJuNPMsaNJu4ITRcOk264Aj1x3s2dLyaTO2pi4goovnOqUoeQZxxecQD9unIBAhhwzbjiwOQDcsyVGnsF4GG_S6UYgPlyRE5qvQYQQuz0Y3IkRgnC6OGYfD9LLbIPP38sC5boEr3KZc0JaUx0X5CtmPLebdUtNODqFqzUhYaFumlxLd4gLW6OOeY5dlEr6FqXNBpyoXMMAUt_Rddwpu3qtuQ4U--Sx_KEPApuqfj0_jwln99cfDp_xy4_vn1_fnbJvNSiMeF3I5qJI0zzYDR4GIwxgXs1TcqFQfPBBOyQ0QGUDnoYduC1HKZeMXKWp-TlwXdf8rcNa7NrrB6XxSXMW7V8NKOSqnt39MU_6HXeSurTWQFS9e2NQnSKHyhfcq0Fg92XuLpyaznYu1jsIRbbY7F3sVjZNc_vnbdpxfmP4ncOHRAHoPav9BXL39b_d_0FoqGZmg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2035022922</pqid></control><display><type>article</type><title>Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Giusti, Massimo ; Mittica, Miranda ; Comite, Paola ; Campana, Claudia ; Gay, Stefano ; Mussap, Michele</creator><creatorcontrib>Giusti, Massimo ; Mittica, Miranda ; Comite, Paola ; Campana, Claudia ; Gay, Stefano ; Mussap, Michele</creatorcontrib><description>Purpose
In recent years, anti-Mullerian hormone (AMH) has been considered a reliable index of ovarian reserve. There are few data on AMH values in thyroid cancer. The aim of this study was to evaluate AMH levels in pre-menopausal women with a history of low-risk thyroid cancer.
Methods
Thirty-four women (aged 40.7 ± 6.7 years) were studied 7.1 ± 0.9 years after surgery and at least one RAI treatment. A group of 23 thyroid cancer women (41.6 ± 7.4 years) who had undergone only thyroidectomy served as controls. AMH, follicle-stimulating hormone (FSH) and estradiol were assayed on days 2–3, and prolactin and progesterone levels on days 21–24 of the menstrual cycle.
Results
Pregnancy (RAI group 62%; control group 61%) and miscarriage rates (18% and 26%) were similar. AMH levels were similar in the RAI (10.7 ± 1.7 pmol/l) and control (17.5 ± 4.7 pmol/l) groups. Regular menses were reported in 41% and 52% of RAI and control subjects, respectively. Non-ovulatory cycles were noted in 26% and 35% of RAI and control women, respectively. AMH levels were found to be negatively correlated with age (RAI group
P
= 0.0003; control group
P
= 0.0001) and FSH, and positively correlated with progesterone, but not with the other hormonal parameters.
Conclusions
AMH should replace FSH in the evaluation of gonadal reserve in pre-menopausal thyroid cancer women. At present, age is the only predictor of AMH levels. About one out of two women with a history of thyroid cancer suffers from menstrual dysregulation, but infertility must be considered a low risk.</description><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-017-1510-3</identifier><identifier>PMID: 29302874</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>17β-Estradiol ; Adult ; Anti-Mullerian Hormone - blood ; Diabetes ; Endocrinology ; Female ; Follicle-stimulating hormone ; Health risk assessment ; Humanities and Social Sciences ; Humans ; Infertility ; Internal Medicine ; Iodine Radioisotopes - therapeutic use ; Medicine ; Medicine & Public Health ; Menstrual Cycle ; Menstruation ; Middle Aged ; multidisciplinary ; Original Article ; Pregnancy ; Pregnancy Rate ; Premenopause ; Progesterone ; Prolactin ; Science ; Surgery ; Thyroid cancer ; Thyroid Neoplasms - blood ; Thyroid Neoplasms - radiotherapy ; Thyroidectomy</subject><ispartof>Endocrine, 2018-06, Vol.60 (3), p.516-523</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>Copyright Springer Science & Business Media 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-2c69e8b1e0bd4870c04888f1c5bb5af47148fec6987f057f74460c734b98783d3</citedby><cites>FETCH-LOGICAL-c372t-2c69e8b1e0bd4870c04888f1c5bb5af47148fec6987f057f74460c734b98783d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-017-1510-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-017-1510-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29302874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giusti, Massimo</creatorcontrib><creatorcontrib>Mittica, Miranda</creatorcontrib><creatorcontrib>Comite, Paola</creatorcontrib><creatorcontrib>Campana, Claudia</creatorcontrib><creatorcontrib>Gay, Stefano</creatorcontrib><creatorcontrib>Mussap, Michele</creatorcontrib><title>Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer</title><title>Endocrine</title><addtitle>Endocrine</addtitle><addtitle>Endocrine</addtitle><description>Purpose
In recent years, anti-Mullerian hormone (AMH) has been considered a reliable index of ovarian reserve. There are few data on AMH values in thyroid cancer. The aim of this study was to evaluate AMH levels in pre-menopausal women with a history of low-risk thyroid cancer.
Methods
Thirty-four women (aged 40.7 ± 6.7 years) were studied 7.1 ± 0.9 years after surgery and at least one RAI treatment. A group of 23 thyroid cancer women (41.6 ± 7.4 years) who had undergone only thyroidectomy served as controls. AMH, follicle-stimulating hormone (FSH) and estradiol were assayed on days 2–3, and prolactin and progesterone levels on days 21–24 of the menstrual cycle.
Results
Pregnancy (RAI group 62%; control group 61%) and miscarriage rates (18% and 26%) were similar. AMH levels were similar in the RAI (10.7 ± 1.7 pmol/l) and control (17.5 ± 4.7 pmol/l) groups. Regular menses were reported in 41% and 52% of RAI and control subjects, respectively. Non-ovulatory cycles were noted in 26% and 35% of RAI and control women, respectively. AMH levels were found to be negatively correlated with age (RAI group
P
= 0.0003; control group
P
= 0.0001) and FSH, and positively correlated with progesterone, but not with the other hormonal parameters.
Conclusions
AMH should replace FSH in the evaluation of gonadal reserve in pre-menopausal thyroid cancer women. At present, age is the only predictor of AMH levels. About one out of two women with a history of thyroid cancer suffers from menstrual dysregulation, but infertility must be considered a low risk.</description><subject>17β-Estradiol</subject><subject>Adult</subject><subject>Anti-Mullerian Hormone - blood</subject><subject>Diabetes</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Follicle-stimulating hormone</subject><subject>Health risk assessment</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Infertility</subject><subject>Internal Medicine</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Menstrual Cycle</subject><subject>Menstruation</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Original Article</subject><subject>Pregnancy</subject><subject>Pregnancy Rate</subject><subject>Premenopause</subject><subject>Progesterone</subject><subject>Prolactin</subject><subject>Science</subject><subject>Surgery</subject><subject>Thyroid cancer</subject><subject>Thyroid Neoplasms - blood</subject><subject>Thyroid Neoplasms - radiotherapy</subject><subject>Thyroidectomy</subject><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc2OFSEQhYnROD_6AG4MiRs3aAHNhV5OJuNPMsaNJu4ITRcOk264Aj1x3s2dLyaTO2pi4goovnOqUoeQZxxecQD9unIBAhhwzbjiwOQDcsyVGnsF4GG_S6UYgPlyRE5qvQYQQuz0Y3IkRgnC6OGYfD9LLbIPP38sC5boEr3KZc0JaUx0X5CtmPLebdUtNODqFqzUhYaFumlxLd4gLW6OOeY5dlEr6FqXNBpyoXMMAUt_Rddwpu3qtuQ4U--Sx_KEPApuqfj0_jwln99cfDp_xy4_vn1_fnbJvNSiMeF3I5qJI0zzYDR4GIwxgXs1TcqFQfPBBOyQ0QGUDnoYduC1HKZeMXKWp-TlwXdf8rcNa7NrrB6XxSXMW7V8NKOSqnt39MU_6HXeSurTWQFS9e2NQnSKHyhfcq0Fg92XuLpyaznYu1jsIRbbY7F3sVjZNc_vnbdpxfmP4ncOHRAHoPav9BXL39b_d_0FoqGZmg</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Giusti, Massimo</creator><creator>Mittica, Miranda</creator><creator>Comite, Paola</creator><creator>Campana, Claudia</creator><creator>Gay, Stefano</creator><creator>Mussap, Michele</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180601</creationdate><title>Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer</title><author>Giusti, Massimo ; Mittica, Miranda ; Comite, Paola ; Campana, Claudia ; Gay, Stefano ; Mussap, Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-2c69e8b1e0bd4870c04888f1c5bb5af47148fec6987f057f74460c734b98783d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>17β-Estradiol</topic><topic>Adult</topic><topic>Anti-Mullerian Hormone - blood</topic><topic>Diabetes</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Follicle-stimulating hormone</topic><topic>Health risk assessment</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Infertility</topic><topic>Internal Medicine</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Menstrual Cycle</topic><topic>Menstruation</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Original Article</topic><topic>Pregnancy</topic><topic>Pregnancy Rate</topic><topic>Premenopause</topic><topic>Progesterone</topic><topic>Prolactin</topic><topic>Science</topic><topic>Surgery</topic><topic>Thyroid cancer</topic><topic>Thyroid Neoplasms - blood</topic><topic>Thyroid Neoplasms - radiotherapy</topic><topic>Thyroidectomy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giusti, Massimo</creatorcontrib><creatorcontrib>Mittica, Miranda</creatorcontrib><creatorcontrib>Comite, Paola</creatorcontrib><creatorcontrib>Campana, Claudia</creatorcontrib><creatorcontrib>Gay, Stefano</creatorcontrib><creatorcontrib>Mussap, Michele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giusti, Massimo</au><au>Mittica, Miranda</au><au>Comite, Paola</au><au>Campana, Claudia</au><au>Gay, Stefano</au><au>Mussap, Michele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><addtitle>Endocrine</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>60</volume><issue>3</issue><spage>516</spage><epage>523</epage><pages>516-523</pages><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Purpose
In recent years, anti-Mullerian hormone (AMH) has been considered a reliable index of ovarian reserve. There are few data on AMH values in thyroid cancer. The aim of this study was to evaluate AMH levels in pre-menopausal women with a history of low-risk thyroid cancer.
Methods
Thirty-four women (aged 40.7 ± 6.7 years) were studied 7.1 ± 0.9 years after surgery and at least one RAI treatment. A group of 23 thyroid cancer women (41.6 ± 7.4 years) who had undergone only thyroidectomy served as controls. AMH, follicle-stimulating hormone (FSH) and estradiol were assayed on days 2–3, and prolactin and progesterone levels on days 21–24 of the menstrual cycle.
Results
Pregnancy (RAI group 62%; control group 61%) and miscarriage rates (18% and 26%) were similar. AMH levels were similar in the RAI (10.7 ± 1.7 pmol/l) and control (17.5 ± 4.7 pmol/l) groups. Regular menses were reported in 41% and 52% of RAI and control subjects, respectively. Non-ovulatory cycles were noted in 26% and 35% of RAI and control women, respectively. AMH levels were found to be negatively correlated with age (RAI group
P
= 0.0003; control group
P
= 0.0001) and FSH, and positively correlated with progesterone, but not with the other hormonal parameters.
Conclusions
AMH should replace FSH in the evaluation of gonadal reserve in pre-menopausal thyroid cancer women. At present, age is the only predictor of AMH levels. About one out of two women with a history of thyroid cancer suffers from menstrual dysregulation, but infertility must be considered a low risk.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29302874</pmid><doi>10.1007/s12020-017-1510-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-008X |
| ispartof | Endocrine, 2018-06, Vol.60 (3), p.516-523 |
| issn | 1355-008X 1559-0100 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1989535487 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 17β-Estradiol Adult Anti-Mullerian Hormone - blood Diabetes Endocrinology Female Follicle-stimulating hormone Health risk assessment Humanities and Social Sciences Humans Infertility Internal Medicine Iodine Radioisotopes - therapeutic use Medicine Medicine & Public Health Menstrual Cycle Menstruation Middle Aged multidisciplinary Original Article Pregnancy Pregnancy Rate Premenopause Progesterone Prolactin Science Surgery Thyroid cancer Thyroid Neoplasms - blood Thyroid Neoplasms - radiotherapy Thyroidectomy |
| title | Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T23%3A11%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-M%C3%BCllerian%20hormone%20in%20pre-menopausal%20females%20after%20ablative%20radioiodine%20treatment%20for%20differentiated%20thyroid%20cancer&rft.jtitle=Endocrine&rft.au=Giusti,%20Massimo&rft.date=2018-06-01&rft.volume=60&rft.issue=3&rft.spage=516&rft.epage=523&rft.pages=516-523&rft.issn=1355-008X&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-017-1510-3&rft_dat=%3Cproquest_cross%3E1989535487%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2035022922&rft_id=info:pmid/29302874&rfr_iscdi=true |